Provided by Tiger Trade Technology Pte. Ltd.

Atea Pharmaceuticals, Inc.

5.51
+0.08001.47%
Volume:100.10K
Turnover:545.71K
Market Cap:441.93M
PE:-2.63
High:5.53
Open:5.39
Low:5.25
Close:5.43
52wk High:6.45
52wk Low:2.78
Shares:80.20M
Float Shares:60.05M
Volume Ratio:0.44
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0959
EPS(LYR):-1.9430
ROE:-58.14%
ROA:-36.72%
PB:2.16
PE(LYR):-2.84

Loading ...

Atea Pharmaceuticals Q1 EPS USD -0.57

THOMSON REUTERS
·
May 13

Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate

Benzinga Earnings
·
May 13

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 13

Atea Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
May 09

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

GlobeNewswire
·
May 05

Atea Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 28

Atea Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Mar 10

Analysts Conflicted on These Healthcare Names: Atea Pharmaceuticals (AVIR), InnovAge Holding (INNV) and Kura Oncology (KURA)

TIPRANKS
·
Mar 06

Atea Pharmaceuticals Q4 net loss widens

Reuters
·
Mar 06

Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate

Benzinga Earnings
·
Mar 06

Atea Pharma Q4 net loss hits USD 44.9 million, R&D expense rises to USD 47.8 million (+86.2%)

Reuters
·
Mar 06

BRIEF-Atea Pharmaceuticals Q4 Basic EPS USD -0.57

Reuters
·
Mar 06

Atea Pharmaceuticals Q4 Operating Income USD -54.934 Million

THOMSON REUTERS
·
Mar 06

Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 06

Atea Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
Mar 04

Atea Pharmaceuticals Inc. Schedules Q4 and Full-Year Financial Results Conference Call

Reuters
·
Feb 26

BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587

Reuters
·
Feb 24

Atea Pharmaceuticals to Launch Mid-2026 Phase 1 Trial of AT-587 for Hepatitis E

Reuters
·
Feb 24

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of at-587 for Treatment of Hepatitis E Virus at Croi 2026

THOMSON REUTERS
·
Feb 24